The failure of the Dimebon trial prompted me to think about how best to select drugs to move through the pipeline from preclinical research to clinical trials. It seems to me that knowing how the drug works, how it acts on a therapeutic target, is an important consideration in prioritizing potential treatments.
Dimebon was not successful in its Phase III trial in Huntington's disease patients. These results are disappointing but not surprising after the unsuccessful trial in Alzheimer's patients.
The take home message here is that in choosing drugs from the pipeline to move into clinical trials, we should give our strongest consideration to drugs where the mechanism is known. It was never clear how Dimebon might work.
The Phase III clinical trial for creatine is still enrolling. We have updated information about the trial below.
The press release below involves a correction to previously announced results of the Huntexil (ACR16) clinical trial in Europe.
ACR16 improves voluntary and involuntary movement. This is wonderful news!
Medivation is sponsoring a randomized, double-Blind, placebo-controlled, Phase III trial of Dimebon in patients with mild to moderate Huntington’s Disease